Phoenix and Raven Become First Canadian Telehealth Platforms to Offer Generic Semaglutide
Following Health Canada's approval of generic semaglutide on April 28, 2026, telehealth platforms Phoenix and Raven have moved immediately to offer it to patients — making them the first in Canada to do so and cementing Canada's position as the first G7 country to bring a generic GLP-1 to market.
Editor
5/26/20261 min read
Canadian telehealth platforms Phoenix and Raven announced on May 20, 2026 that they have become the first platforms in Canada to offer generic semaglutide to patients. The launch follows Health Canada's approval of the drug on April 28, 2026, an approval that positioned Canada as the first G7 country to permit a generic version of semaglutide — the active ingredient in Ozempic and Wegovy.
Phoenix and Raven are Canadian telehealth companies operating in the men's health and weight management space. The launch of generic semaglutide represents a significant product expansion, offering patients access to GLP-1 weight loss medication at lower cost than branded equivalents. Multiple generic formulations are now available through both platforms, providing patients with choice and price competition.
The timing is notable: in the US, platforms like Hims & Hers are simultaneously exiting the compounded semaglutide market under regulatory pressure and pivoting to branded products. Canada, by contrast, is moving in the opposite direction — creating a distinct regulatory and commercial environment for GLP-1 access in North America. The Canadian generic approval removes the dependency on shortage exemptions that enabled compounded versions in the US, giving Canadian telehealth operators a legally stable pathway for GLP-1 prescribing.
This move signals that Canada is emerging as a key battleground for men's telehealth expansion. With generic pricing, telehealth delivery, and regulatory clarity now aligned, platforms that move quickly — as Phoenix and Raven have — stand to capture early market share in Canada's GLP-1 weight management segment, which disproportionately serves men managing metabolic and hormonal health.